全自动脑脊液与新型血浆生物标志物与尸检阿尔茨海默病神经病理的关联
本研究在45例尸检证实的痴呆患者中,比较全自动Elecsys脑脊液生物标志物与血浆p-tau181对AD神经病理的诊断准确性。结果显示脑脊液Aβ1-42、t-tau、p-tau181及其比值能高精度区分病理确诊的AD痴呆与健康对照及非AD痴呆;血浆p-tau181和NfL也能准确区分AD与健康对照,但仅p-tau181能区分AD与非AD痴呆。
要点
- 全自动脑脊液t-tau和p-tau181可高精度区分尸检确诊AD与其他痴呆。
- 脑脊液Aβ1-42最佳检测中高Thal淀粉样蛋白相位,p-tau181最佳检测神经炎性斑块和Braak分期。
- 血浆p-tau181可准确区分AD与健康对照及非AD痴呆,但病理特异性弱于脑脊液。
核心结论
- 全自动Elecsys脑脊液生物标志物能在生前以极高判别准确性检测AD神经病理改变。
- 初步发现支持血浆p-tau181作为易获取、可扩展的AD病理生物标志物。
研究设计与样本
- 研究纳入45例生前有脑脊液Elecsys生物标志物且死后接受标准化AD和非AD神经病理评估的个体。
- 其中26例亚组分析了生前血浆p-tau181和神经丝轻链(NfL)水平。
- 参照生物标志物值来自146例淀粉样蛋白PET阴性的健康对照(HC)。
主要发现
- 所有脑脊液生物标志物清楚区分病理确诊的AD痴呆(n=27)与HC(AUC 0.86-1.00)。
- 脑脊液t-tau、p-tau181及其与Aβ1-42的比值准确区分病理确诊AD与非AD痴呆(n=8;AUC 0.94-0.97)。
- 中高Thal淀粉样蛋白相位最佳由脑脊液Aβ1-42检测(AUC 0.91 [95%CI 0.81-1])。
- 中高CERAD神经炎性斑块评分和Braak tau分期最佳由脑脊液p-tau181检测(AUC分别为0.89 [0.79-0.99]和0.88 [0.77-0.99])。
- 血浆p-tau181(AUC 0.91 [0.86-0.96])和NfL(AUC 0.93 [0.87-0.99])准确区分病理确诊AD(n=14)与HC;仅p-tau181区分AD与非AD痴呆(n=4;AUC 0.96 [0.88-1.00])。
关键数值与推荐
- Elecsys生物标志物最佳截断值:Aβ1-42为1,097 pg/mL,t-tau为229 pg/mL,p-tau181为19 pg/mL。
- 血浆p-tau181对神经炎性斑块的病理特异性AUC为0.75 [0.52-0.98],对Braak分期的AUC为0.71 [0.44-0.98]。
临床怎么用
- 全自动脑脊液t-tau和p-tau181可用于区分尸检确诊AD与其他痴呆(Class II证据)。
- 血浆p-tau181可作为易获取、可扩展的AD病理生物标志物,但病理特异性需进一步验证。
局限性
- 血浆亚组样本量小(AD n=14,非AD痴呆 n=4),结论为初步发现。
- 血浆p-tau181对神经炎性斑块和Braak分期的病理特异性弱于脑脊液p-tau181,置信区间宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study CSF biomarkers of Alzheimer disease (AD) analyzed by fully automated Elecsys immunoassays compared to neuropathologic gold standards and to compare their accuracy to plasma phosphorylated tau (p-tau181) measured with a novel single molecule array method. METHODS: We studied antemortem Elecsys-derived CSF biomarkers in 45 individuals who underwent standardized postmortem assessments of AD and non-AD neuropathologic changes at autopsy. In a subset of 26 participants, we also analyzed antemortem levels of plasma p-tau181 and neurofilament light (NfL). Reference biomarker values were obtained from 146 amyloid-PET-negative healthy controls (HC). RESULTS: All CSF biomarkers clearly distinguished pathology-confirmed AD dementia (n = 27) from HC (area under the curve [AUC] 0.86-1.00). CSF total tau (t-tau), p-tau181, and their ratios with β-amyloid1-42 (Aβ1-42) also accurately distinguished pathology-confirmed AD from non-AD dementia (n = 8; AUC 0.94-0.97). In pathology-specific analyses, intermediate to high Thal amyloid phases were best detected by CSF Aβ1-42 (AUC [95% confidence interval] 0.91 [0.81-1]), while intermediate to high scores for Consortium to Establish a Registry for Alzheimer's Disease neuritic plaques and Braak tau stages were best detected by CSF p-tau181 (AUC 0.89 [0.79-0.99] and 0.88 [0.77-0.99], respectively). Optimal Elecsys biomarker cutoffs were derived at 1,097, 229, and 19 pg/mL for Aβ1-42, t-tau, and p-tau181. In the plasma subsample, both plasma p-tau181 (AUC 0.91 [0.86-0.96]) and NfL (AUC 0.93 [0.87-0.99]) accurately distinguished those with pathology-confirmed AD (n = 14) from HC. However, only p-tau181 distinguished AD from non-AD dementia cases (n = 4; AUC 0.96 [0.88-1.00]) and showed a similar, although weaker, pathologic specificity for neuritic plaques (AUC 0.75 [0.52-0.98]) and Braak stage (AUC 0.71 [0.44-0.98]) as CSF p-tau181. CONCLUSION: Elecsys-derived CSF biomarkers detect AD neuropathologic changes with very high discriminative accuracy in vivo. Preliminary findings support the use of plasma p-tau181 as an easily accessible and scalable biomarker of AD pathology. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that fully automated CSF t-tau and p-tau181 measurements discriminate between autopsy-confirmed AD and other dementias.
引用
- Grothe MJ, Moscoso A, Ashton NJ, et al. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology. 2021. PMID: 34266917. doi:10.1212/WNL.0000000000012513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。